David Shapiro joins Design Therapeutics (DSGN) board with equity awards
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Design Therapeutics, Inc. reported that its Board appointed David Shapiro, M.D., as a Class III director effective March 31, 2026, with a term running until the 2027 annual meeting of stockholders. He will also serve on the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation policy, Dr. Shapiro will receive an annual cash retainer of $40,000 for Board service and $5,000 for Nominating Committee service. He was granted an initial option to purchase 60,000 shares of common stock vesting monthly over three years and a prorated annual option for 7,500 shares vesting monthly over one year.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board cash retainer: $40,000 per year
Committee cash retainer: $5,000 per year
Initial option grant: 60,000 shares
+2 more
5 metrics
Board cash retainer
$40,000 per year
Annual cash retainer for Board service under non-employee director policy
Committee cash retainer
$5,000 per year
Annual cash retainer for Nominating and Corporate Governance Committee
Initial option grant
60,000 shares
Initial stock option to Dr. Shapiro, vesting monthly over three years
Prorated annual option
7,500 shares
Prorated annual option grant vesting monthly over one year
Director term end
2027 annual meeting
Term of Class III directorship for Dr. Shapiro
Key Terms
Emerging growth company, Nominating and Corporate Governance Committee, non-employee director compensation policy, indemnification agreement
4 terms
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nominating and Corporate Governance Committee financial
"Dr. Shapiro was also appointed to the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
non-employee director compensation policy financial
"Pursuant to the Company’s current non-employee director compensation policy, (i) Dr. Shapiro is entitled to receive an annual cash retainer"
indemnification agreement regulatory
"The Company and Dr. Shapiro have also entered into the Company’s standard indemnification agreement for the Company’s directors and officers"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
